Newport Premium
Powerful integrated API intelligence with unique analysis
Highlights
- Active ingredient intelligence
- Company intelligence
- Patent information
- Current industry awareness
Intended for
- API/fine Chemicals Business Development
- Competitive Intelligence Professional
- Licensing Professional
Description
Newport Premium (for Generics) is the most advanced product targeting and global business development. Created specifically for demanding professionals in generic pharmaceutical companies, OTC and API manufacturers, it can help identify and evaluate new product development and licensing opportunities ahead of the competition for both small molecules and follow-on biologics. Newport Premium (for Innovators) is the most advanced generic competitive intelligence system. Both systems are used to find qualified sources of active ingredients. Newport products are now used by more than 350 companies operating in more than 50 countries around the world.
Features
- Primary intelligence regarding active ingredients and their manufacturers.
- Regulatory filings in US, Europe, Japan, Korea, India, and China.
- Proprietary analytics regarding companies and products.
- Information regarding 40,000 launched products with 300,000+ brand names containing over 10,000 different active ingredients.
- Information regarding more than 20,000 corporate groups involved with manufacturing and marketing dose products and both small molecule and biologic active ingredients.
- Global patent coverage and detailed commentaries on US patent challenges.
- Data and market exclusivities in US, Europe, Japan, and Korea.
Benefits
- Sophisticated product targeting capabilities. Identify potential products to pursue based on API availability, patent and exclusivity expiries, and sales trends.
- Sophisticated partner targeting capabilities. Identify potential partners based on their portfolio and capabilities.
- Validated information regarding active ingredient manufacturers.
- Seamless integration of data from many sources.
- Global coverage.
- Integrated on-line help, comprehensive training, and technical support.
- Access to team carrying out proprietary research.
Newport is optimized for use in the following web browsers, within a Microsoft® Windows 2000 or Windows XP operating system:
- Microsoft Internet Explorer® 6.0 or higher available from the Microsoft website.
- Mozilla Firefox® 2.0 or higher available from the Mozilla website.
Newport is best viewed at a minimum monitor resolution of 1024 by 768 pixels or higher.
White Paper
The Economic Power of Orphan Drugs
Despite the smaller patient pool for rare disease R&D, the economics of orphan drug development shows great potential for commercialization.
White Paper
What you need to know about the follow-on biologic market in the U.S.: Implications, strategies, and impact
White Paper
Gaining market share in the generic drug industry through acquisitions and partnerships.
White Paper
An Outlook on US Biosimilar Competition
Provides updates and changes associated with biosimilar regulations in the US. Additionally, the paper will identify requirements for success, and the likely early
entrants in the US market.
Case Study
Newport Premium™ (For Generics) helps CordenPharma stand out from its competitors and establish a global brand in the generic and contract manufacturing market.
Case Study
Newport Premium™ (For Generics ) helps SK Chemicals stand out from its competitors and establish a global brand in the Bio-Pharmaceutical market.
Case Study
Brazil’s Institute for Applied Economic Research (IPEA ) Case Study
Newport® proves to be a vital tool for Generic information, business development and global API sourcing intelligence.
Case Study
Newport Premium™ (For Generics) proves to be a vital too l in fast, smart decision making for an API business professional across competitive intelligence, target data, and customers.
Case Study
Newport Premium Testimonial - Global API Manufacturer
How comprehensive scientific and competitive data helps drive growth at a leading global API manufacturer
Article
Is API manufacturing returning to Europe
Article by Shannon Bennett, Pharmaceutical Research Analyst, Published in Speciality Chemicals Magazine, June 2012
Article
With Biosimilars: Stick to Your Strengths
Article by Andrew Bourgoin, Senior Pharmaceutical Research Analyst – Biologics, Published in CHEManager, September 25, 2012
Article
Will API Manufacturing Move out of India and China?
Article by Molly Bowman, Manager Industry Research, Published in CHEManager Europe | April 2012
Article
First to File and Beyond: Paragraph IV Business Strategies
Webinar by Benjamin Burck, Project Manager & Analyst | March 2012
Article
Article by Michael Glessner, Pharmaceutical Research Analyst, Published in CHEManager Europe | No. 11/2012
Article
China increases its actvity in regulated markets
Article by Bob Kennedy, Newport Research Manager, Published in Pharma China | July 2012
Article
Antibiotics — Will Changes to Eastern Regulations Impact the West?
Article by Emily Kimball, Pharmaceutical Research Analyst, Published in CHEManager Europe | No. 6/2012
Article
Trends in Pharmaceutical Outsourcing
Article by Kate Kuhrt, Senior Director of Generics and Content Strategy, CHEManager Europe | July 19, 2012
On-Demand
Read more articles by Thomson Reuters Generics and API Experts
Connect with our experts:
-
Molly Bowman
Manager Industry Research
-
Andrew Bourgoin
Sr Pharma Research Analyst
@AndrewFBourgoin RT @Hospira_Inc: .@PackagingWorld discusses “An Outlook on U.S. #Biosimilar Competition" report highlighting challenges, key players http:/…